Ramiro Ribeiro Biography and Net Worth

Chief Medical Officer of Eyepoint Pharmaceuticals

Ramiro Ribeiro, M.D., Ph.D. is a retinal specialist and the Chief Medical Officer of EyePoint. He leads the Clinical Development, Clinical Operations and Medical Safety teams at EyePoint with a profound commitment in innovation to advance patient care and medical excellence. With over 15 years of experience encompassing clinical practice, academy and pharmaceutical industry, Dr. Ribeiro brings a wealth of expertise to his leadership position. Before joining EyePoint, Dr. Ribeiro served as the Head of Clinical Development at Apellis Pharmaceuticals, where he served as the clinical lead for the successful approval of Syfovre, the first ever therapy for Geographic Atrophy secondary to AMD. Previously, he held roles at Ophthotech (now Iveric Bio), Alcon Pharmaceutical and Acucela, where he made significant contributions to the retina field. Dr. Ribeiro holds a M.D. from Pontifical University of Parana, a Ph.D. from Federal University of Sao Paulo and was a research fellow at University of Southern California.

How do I contact Ramiro Ribeiro?: The corporate mailing address for Dr. Ribeiro and other Eyepoint Pharmaceuticals executives is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. Eyepoint Pharmaceuticals can also be reached via phone at (617) 926-5000 and via email at [email protected]. Learn More on Ramiro Ribeiro's contact information.
Has Ramiro Ribeiro been buying or selling shares of Eyepoint Pharmaceuticals?: Over the course of the past ninety days, Ramiro Ribeiro has sold $727,502.40 in shares of Eyepoint Pharmaceuticals stock. Most recently, Ramiro Ribeiro sold 42,544 shares of the business's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $17.10, for a transaction totalling $727,502.40. Learn More on Ramiro Ribeiro's trading history.
Who are Eyepoint Pharmaceuticals' active insiders?: Eyepoint Pharmaceuticals' insider roster includes Wendy Dicicco (Director), David Jones (Chief Commercial Officer), and Ramiro Ribeiro (Chief Medical Officer). Learn More on Eyepoint Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Eyepoint Pharmaceuticals?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 42,544 shares worth more than $727,502.40. The most recent insider tranaction occured on January, 5th when insider Ramiro Ribeiro sold 42,544 shares worth more than $727,502.40. Insiders at Eyepoint Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Eyepoint Pharmaceuticals.
Information on this page was last updated on 1/5/2026.

Ramiro Ribeiro Insider Trading History at Eyepoint Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/5/2026	Sell	42,544	$17.10	$727,502.40

Ramiro Ribeiro Buying and Selling Activity at Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals Company Overview

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $12.94

$12.79

$13.69

50 Day Range

MA: $15.85

$12.33

$18.85

2 Week Range

Now: $12.94

$3.91

$19.11

Volume

788,161 shs

Average Volume

1,029,658 shs

Market Capitalization

$1.07 billion

P/E Ratio

N/A

Dividend Yield